en · de · es · pt
cardarine-notes.peptides6823.com › News › Identity And Regulatory Status — Research Overview

Identity And Regulatory Status — Research Overview

By Editorial Desk · published 2026-01-28 · last reviewed 2026-02-27 · News

Everything below concerns Reference standard. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-02-27. Where a claim depends on a specific study, the study is described rather than over-claimed.

Identity and Regulatory Status

Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.

Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.

Preclinical Findings and Safety Signals

Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Cardarine at a glance

PropertyValueNotes
Common synonymsGW501516; GW-1516; endurobolGW501516 is the research code
Drug classPPARδ agonistNot a selective androgen receptor modulator
Molecular formulaC21H18F3NO3S2Established chemical formula
Molar mass453.5 g/molCalculated from the formula
Regulatory statusProhibited in sport; not approved as medicineStatus varies by country

Detection, Stability, and Quality

Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.

Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.

Related pages on this site

Detection, Regulation, and Quality Context

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Notes from published material

microbody Any of a diverse class of small membrane-bound organelles or vesicles found in the cells of many eukaryotes, especially plants and animals, usually having some specific metabolic function and occurring in great numbers in certain specialized cell types. Peroxisomes, glyoxysomes, glycosomes, and hydrogenosomes are often considered microbodies.

Shulman proposed that lipid-induced insulin resistance results from the accumulation of sn-1,2-diacylglycerol (DAG) in the plasma membrane, which activates novel protein kinase C (nPKC) isoforms—PKCθ in skeletal muscle and PKCε in liver and white adipose tissue—impairing insulin signaling. Shulman's lab explored interventions such as weight loss, thiazolidinediones, adiponectin, leptin, and liver-targeted mitochondrial protonophores to reverse insulin resistance by lowering plasma membrane DAG and inhibiting the nPKC pathway. He also pioneered 13C and 31P NMR methods to measure ATP synthesis and mitochondrial oxidation in vivo. His team identified age-related declines in mitochondrial fat oxidation linked to insulin resistance in elderly individuals, and in insulin-resistant offspring of people with T2D. They showed that chronic AMPK activation drives mitochondrial biogenesis via increased expression of PGC-1α. Shulman used 13C NMR to quantify rates of hepatic glycogenolysis and gluconeogenesis, showing that the latter accounts for over half of fasting hepatic glucose production following an overnight fast overturning the Cahill hypothesis that hepatic glycogenolysis accounts for >90% of glucose production in humans following an overnight fast.

=== Magazine === OECD Observer, an award-winning magazine, was launched in 1962. The magazine appeared six times a year until 2010, and became quarterly in 2011 with the introduction of the OECD Yearbook, launched for the 50th anniversary of the organisation. The online and mobile editions contained news, analysis, reviews, commentaries and data on global economic, social and environmental challenges and listings of the latest OECD books. An OECD Observer Crossword was introduced in Q2 2013. The OECD Observer was last issued in the fourth quarter of 2019, with a double edition looking ahead at artificial intelligence, and a cover leading on why statistical offices should hire a comedian. The OECD Observer website closed in the first quarter of 2021; the archive can be consulted at www.oecd.org.

Sources: en.wikipedia.org

Background from the literature

=== Prosecution in France === The French government had requested Noriega's extradition after he was convicted of money laundering in 1999. It stated that Noriega had laundered $3 million in drug proceeds by purchasing luxury apartments in Paris. Noriega was convicted in absentia, but French law required a new trial after the subject of an in absentia sentence was apprehended. France had previously made Noriega a Commandeur of the Légion d'honneur in 1987. In August 2007, a U.S. federal judge approved the French government's request to extradite Noriega to France after his release. Noriega appealed his extradition because he claimed France would not honor his legal status as a prisoner of war. Though Noriega had been scheduled to be released in 2007, he remained incarcerated while his appeal was pending in court. The Supreme Court of the United States refused to hear his appeal in January 2010, and in March declined a petition for a rehearing. Two days after the refusal, the District Court for the Southern District of Florida in Miami lifted the stay that was blocking Noriega's extradition. Later that month Noriega's attorney stated that he would travel to France and try to arrange a deal with the French government. Noriega was extradited to France on April 26, 2010. Noriega's lawyers claimed the La Santé Prison, at which he was held, was unfit for a man of his age and rank; the French government refused to grant him prisoner of war status, which he had maintained in the United States.

Phyllostachys nigra, commonly known as black bamboo or purple bamboo (Chinese: 紫竹), is a species of bamboo, native to Hunan Province of China, and is widely cultivated elsewhere. Growing up to 10 meters (35 ft) tall by 5cm (2 in) wide, it forms clumps of slender arching canes which turn black after two or three seasons. The abundant lance-shaped leaves are 4–13 cm (2–5 in) long. Numerous forms and cultivars are available for garden use. The species and the form P. nigra f. henonis have both gained the Royal Horticultural Society's Award of Garden Merit. The form henonis is also known as Henon bamboo and as cultivar 'Henon'.

== Monitoring == It is important to recognize that all described exercise programs were conducted by physicians or physiotherapists during the stable phase of the disease (except Painelli). Patients were monitored closely for indicators of deleterious effects, such as increases in serum creatine kinase, inflammation or weakness. Monitoring of this kind can only be done in conjunction with a medical team that is aware of the risks posed by increased inflammatory response in patients with IIM.

== Medical uses == Several treatment guidelines recommend adding ezetimibe in select high-risk persons in whom LDL goals cannot be achieved by maximally tolerated statin alone. Adding ezetimibe to statin treatment of high blood cholesterol has no effect on overall mortality or cardiovascular mortality, although it significantly reduces the risk of myocardial infarction and stroke. Combining ezetimibe with simvastatin had no effect on overall mortality but did lower the risk of heart attack or stroke in people with prior heart attack. Initiation of ezetimibe along with high-intensity statin therapy at the time of an acute coronary syndrome (ACS) event was associated with significantly better cholesterol reduction at day 7, 1-month, 3-months, and 1-year post-ACS event; which translated into significantly lower recurrent cardiovascular events (death from any cause, major ACS, non-fatal stroke, non-fatal myocardial infarction, and ischemic stroke) post the index event of ACS. Ezetimibe is indicated in the United States as an add-on to dietary measures to reduce levels of certain lipids in people with:

Sources: en.wikipedia.org

Frequently asked questions

Is cardarine a SARM?

No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.

Is cardarine approved for human use?

No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.

Why was its development discontinued?

Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.

What did animal studies show?

Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.

Network